Clinical Impact of the Revised 2019 CLSI Levofloxacin Breakpoints in Patients with Enterobacterales Bacteremia

The Clinical and Laboratory Standards Institute (CLSI) revised the fluoroquinolone MIC breakpoints for Enterobacterales in 2019, based on pharmacokinetic/pharmacodynamic analyses. However, clinical evidence supporting these breakpoint revisions is limited. A retrospective study was conducted at 3 ho...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Antimicrob Agents Chemother
Main Authors: Huang, Ho-Yin, Wang, Chu-Feng, Lu, Po-Liang, Tseng, Sung-Pin, Wang, Ya-Ling, Chen, Tun-Chieh, Chang, Ko, Tu, Hung-Pin, Lin, Shang-Yi
Formato: Artigo
Idioma:Inglês
Publicado: American Society for Microbiology 2021
Assuntos:
Clinical Therapeutics
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC8315969/
https://ncbi.nlm.nih.gov/pubmed/33782006
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.00074-21
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares